argenex SE (ARGX) vs Moderna, Inc. (MRNA)
argenex SE and Moderna, Inc. are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $78.8B against $60.2B — 1.3× the size. Moderna, Inc. has negative trailing earnings, so its P/E is not meaningful; argenex SE trades at 34.6×. argenex SE grew revenue faster over the last twelve months: 70.6% against −27.6%. argenex SE has the higher net margin (32.2% vs −141.4%) and the higher return on invested capital (20.7% vs −93.5%). Across the 18 metrics below, argenex SE leads on 18 and Moderna, Inc. on 0.
Valuation
Profitability
| Metric | ARGX | MRNA | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.15% | 23.38% | 65.16% |
| Operating margin | 30.06% | (149.01%) | 0.00% |
| Net margin | 32.20% | (141.43%) | 0.00% |
| Free cash flow margin | 25.87% | (55.83%) | 0.00% |
| Return on equity | 27.07% | (39.00%) | (57.72%) |
| Return on assets | 19.95% | (27.43%) | (49.22%) |
| Return on invested capital | 20.71% | (93.47%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack